CITIUS ONCOLOGY, INC. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Leonard Mazur (CEO/Chairman) and Jaime Bartushak (CFO) issued standard Sarbanes-Oxley 302 and 906 certifications on August 14, 2026 for the Q2 2026 10-Q. Both officers certify the report contains no untrue material statements, financial statements fairly present the company's condition, and disclosure controls and internal controls are effective. No specific material weaknesses, deficiencies, or frauds were disclosed.
Why this rating
Standard SOX certifications are routine disclosure. No substantive operational, financial, or control changes reported; no anomalies flagged.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.